Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Whooping cough is caused by Bordetella pertussis, and it remains a public health concern. Whole-cell pertussis vaccines have been commonly employed for expanded immunization. There is no doubt of the efficacy of whole cell pertussis vaccine, but it is necessary to improve the vaccine to decrease its toxicity.
Objectives: In this study, an inactivation process of dealing with pertussis bacteria is optimized in order to decrease the bacteria content in human doses of vaccines and reduce the vaccine's toxicity.
Materials And Methods: The bacterial suspensions of pertussis strains 509 and 134 were divided into 21 sample parts from F1 to F21 and inactivated under different conditions. The inactivated suspensions of both strains were tested for opacity, non-viability, agglutination, purity, and sterility; the same formulation samples that passed quality tests were then pooled together. The pool of inactivated suspensions were analyzed for sterility, agglutination, opacity, specific toxicity, and potency.
Results: The harvest of both bacterial strains showed purity. The opacity of various samples were lost under different treatment conditions by heat from 8% to 12%, formaldehyde 6% to 8%, glutaraldehyde 6% to 8%, and thimerosal 5% to 8%. Tests on suspensions after inactivation and on pooled suspensions showed inactivation conditions not degraded agglutinins of both strains. The samples of F2, F4, F8, F12, F15, and F17 passed the toxicity test. The potency (ED50) of these samples showed following order F17 > F12 > F8 > F15, F4 > F2, and F17 revealed higher potency compared to other formulations.
Conclusions: It can be concluded that F17 showed desirable outcomes in the toxicity test and good immunogenicity with a low bacterial number content. Consequently, lower adverse effects and good immunogenicity are foreseeable for vaccine preparation with this method.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5035437 | PMC |
| http://dx.doi.org/10.5812/jjm.34153 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Evaluating the Relationship Between the Introduction of the Acellular Pertussis Vaccine and Whooping Cough Resurgence in the United States.
Vaccines (Basel)
August 2025
School of Public Health and Health Sciences, California State University, Dominguez Hills, Carson, CA 90747, USA.
: The whole cell pertussis vaccine was introduced in the United States in the 1940s and switched to the acellular pertussis vaccine partially in 1992 and completely in 1997. This study examines the relationship between the resurgence of pertussis in the United States and the change in the type of pertussis vaccines. : Pertussis cases from 1922 to 2024 were obtained from the CDC's national notifiable disease surveillance system, and vaccination coverage was obtained from the WHO.
View Article and Find Full Text PDFResurgence of pertussis: whopping the '100-day cough'.
Curr Opin Pediatr
October 2025
Department of Child (Pediatrics) and Adolescent Health, (Pediatric Infectious Diseases, Epidemiology and Public Health), University of the West Indies.
Purpose Of Review: Against the WHO's report of 84% diphtheria-pertussis-tetanus (DPT) primary vaccination coverage globally, the resurgence of pertussis (whooping cough), contributing factors and measures to control it are described.
Recent Findings: USA and China, with 94-97% primary DPT immunization uptake, reported a 6-fold and 65-fold increase in pertussis between two time periods in 2023 and 2024. The global post-COVID-19 pertussis epidemic is trending towards a shift from infants towards older persons.
Evaluation of Immune Responses to Tdap Booster During Pregnancy in Women Who Received Whole Cell or Acellular Pertussis Vaccines During Childhood.
Emerg Microbes Infect
August 2025
Department of Microbial Infection and Immunity, The Ohio State University, Columbus OH 43210.
Pertussis, caused by (), results in severe morbidity and mortality in infants. Since 2012, the tetanus, diphtheria and pertussis (Tdap) booster vaccine is recommended during every pregnancy to protect infants who are too young to be immunized. While infants of whole cell pertussis vaccine (wPV)-primed pregnant individuals are well protected from severe disease, the effectiveness of this strategy has not been assessed in acellular pertussis vaccine (aPV)-primed pregnant women.
View Article and Find Full Text PDFInnovative adjuvant strategies for next-generation pertussis vaccines.
Hum Vaccin Immunother
December 2025
State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, China.
The acellular pertussis (aP) vaccine has increasingly replaced the whole-cell pertussis (wP) vaccine due to its superior safety profile. However, the aP vaccine is less effective at preventing infection and transmission of , highlighting the need for more effective aP vaccines. Current aP vaccines do not elicit the robust cellular immunity necessary to eliminate intracellular bacteria and do not induce sufficient mucosal immunity to prevent bacterial colonization in the upper respiratory tract.
View Article and Find Full Text PDFImmunologic profiling of the infant immune response to whole-cell and acellular pertussis vaccines.
NPJ Vaccines
August 2025
Instituto de Investigación Nutricional, Lima, Peru.
Despite robust antibody responses, immunity induced by acellular pertussis vaccine (DTaP) wanes over time and risk of pertussis seems to be lower in children who receive whole-cell vaccine (DTP) as their first dose. To interrogate the early immunologic response to pertussis vaccine, we enrolled 56 healthy infants who received either DTP or DTaP at 2-, 4-, 6-, and 18-months of age. RNA-sequencing and ribosome profiling of PBMC were performed prior to vaccination (Day 1) and on either Day 2 or Day 8.
View Article and Find Full Text PDF